8-K: Arcus Biosciences Discontinues Phase 3 Lung Cancer Study

Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121 study for metastatic non-small cell lung cancer due to futility, and Gilead will not extend its option rights for early-stage pipeline programs.

Summary

• Arcus Biosciences has decided to discontinue the Phase 3 STAR-121 study evaluating domvanalimab plus zimberelimab and chemotherapy against pembrolizumab plus chemotherapy for first-line metastatic non-small cell lung cancer.
• This decision was based on a recommendation from the Independent Data Monitoring Committee (IDMC) following a pre-planned futility analysis.
• No new safety issues were identified during regular IDMC reviews.
• The STAR-121 study also explored zimberelimab and chemotherapy as an exploratory endpoint, showing overall survival consistent with pembrolizumab plus chemotherapy.
• The Phase 2 EDGE-Lung study will also be discontinued.
• Gilead Sciences, Inc. will not make the option continuation payment, ending its option rights for additional early-stage pipeline programs by July 14, 2026.
• Gilead will retain existing time-limited options for specific programs including AB801, AB598, AB102, and a TNF small molecule inhibitor.
• Arcus Biosciences retains full rights to casdatifan and its development program, except for rights licensed to Taiho in Japan and certain other Asian territories.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the discontinuation of a Phase 3 trial for futility and the termination of Gilead's option rights on early-stage programs.

Positives

• No new safety issues were identified in the STAR-121 study during regular reviews by the IDMC.
• Zimberelimab plus chemotherapy performed consistently with respect to overall survival compared to pembrolizumab plus chemotherapy in the STAR-121 study's exploratory endpoint.
• Arcus Biosciences retains full rights to the casdatifan development program, excluding territories licensed to Taiho.

Negatives

• The Phase 3 STAR-121 study for metastatic non-small cell lung cancer was discontinued due to futility.
• Gilead Sciences, Inc. has decided not to make the option continuation payment, ending its option rights for additional early-stage pipeline programs by July 14, 2026.
• The Phase 2 EDGE-Lung study will also be discontinued.

Risks

• The discontinuation of the STAR-121 study due to futility indicates a potential lack of efficacy for the investigated treatment regimen in first-line metastatic non-small cell lung cancer.
• The termination of Gilead's option rights for early-stage pipeline programs could impact future development and commercialization opportunities for Arcus Biosciences.
• Uncertainty regarding next steps for patients currently enrolled in the discontinued STAR-121 and EDGE-Lung studies.

Future Outlook

Gilead will not have option rights to additional early-stage pipeline programs, but will maintain existing time-limited options to specific programs. Arcus Biosciences retains full rights to casdatifan and its development program in most territories. Gilead is working with investigators to determine next steps for patients in the discontinued studies.

Management Comments

• The decision to discontinue STAR-121 was based on the recommendation from the Independent Data Monitoring Committee (IDMC), following its review of data from a pre-planned futility analysis.
• Safety was not assessed at this futility analysis; however, no new safety issues have been identified during regular reviews by the IDMC.

Industry Context

StockSavvy.ai notes that the discontinuation of a Phase 3 trial due to futility is a significant setback for Arcus Biosciences and highlights the challenges in developing effective treatments for metastatic non-small cell lung cancer, an area with intense competition and ongoing research.

Stakeholder Impact

• Shareholders may experience a negative impact on stock price due to the discontinuation of a key clinical trial and reduced potential future revenue from early-stage pipeline programs.
• Patients enrolled in the STAR-121 and EDGE-Lung studies will be affected by the discontinuation of these trials, with next steps to be determined by Gilead and investigators.
• The company's research and development strategy may need to be re-evaluated following these setbacks.

Next Steps

• Gilead is communicating with investigators to determine appropriate next steps for patients in the STAR-121 and EDGE-Lung studies.
• Gilead's option rights for additional early-stage pipeline programs will end on July 14, 2026.

Key Dates

Recommendation

The discontinuation of a Phase 3 trial due to futility and the loss of Gilead's option rights on early-stage programs represent significant negative developments. However, the company retains rights to other programs, and the existing collaboration with Gilead continues for certain assets. A 'hold' recommendation reflects the uncertainty and negative news, balanced by the company's ongoing pipeline and existing partnerships.

Keywords

Arcus Biosciences, STAR-121, Gilead Sciences, non-small cell lung cancer, domvanalimab, zimberelimab, futility, clinical trial discontinuation